These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23447342)

  • 1. Advanced breast cancers increasing in young women.
    BMJ; 2013 Feb; 346():f1234. PubMed ID: 23447342
    [No Abstract]   [Full Text] [Related]  

  • 2. Breast cancer biology and ethnic disparities in breast cancer mortality in new zealand: a cohort study.
    Seneviratne S; Lawrenson R; Scott N; Kim B; Shirley R; Campbell I
    PLoS One; 2015; 10(4):e0123523. PubMed ID: 25849101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced breast cancer in young women.
    Peres J
    J Natl Cancer Inst; 2013 Sep; 105(17):1257-8. PubMed ID: 23956454
    [No Abstract]   [Full Text] [Related]  

  • 4. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools.
    Foldi J; O'Meara T; Marczyk M; Sanft T; Silber A; Pusztai L
    J Clin Oncol; 2019 Jun; 37(16):1365-1369. PubMed ID: 30943126
    [No Abstract]   [Full Text] [Related]  

  • 6. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer in 30-year-old or younger patients: clinicopathologic characteristics and prognosis.
    Yao Y; Cao M; Fang H; Xie J
    World J Surg Oncol; 2015 Feb; 13():38. PubMed ID: 25889848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is adjuvant chemotherapy omissible in women with T1-2 stage, node-positive, luminal A type breast cancer?
    Kwak HY; Chae BJ; Eom YH; Hong YR; Seo JB; Bae JS; Jung SS; Song BJ
    J Chemother; 2015 Oct; 27(5):290-6. PubMed ID: 25974160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.
    Pesce C; Liederbach E; Wang C; Lapin B; Winchester DJ; Yao K
    Ann Surg Oncol; 2014 Oct; 21(10):3231-9. PubMed ID: 25081341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A step in the right direction.
    Swain SM
    J Clin Oncol; 2006 Aug; 24(23):3717-8. PubMed ID: 16720679
    [No Abstract]   [Full Text] [Related]  

  • 11. The Impact of Ki-67 on Immunostaining in Classification of Luminal Subtypes of breast Cancer.
    Lagios MD
    Breast J; 2015; 21(5):463-4. PubMed ID: 26332073
    [No Abstract]   [Full Text] [Related]  

  • 12. Osteopontin-c is a selective marker of breast cancer.
    Mirza M; Shaughnessy E; Hurley JK; Vanpatten KA; Pestano GA; He B; Weber GF
    Int J Cancer; 2008 Feb; 122(4):889-97. PubMed ID: 17960616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
    Horn J; Alsaker MD; Opdahl S; Engstrøm MJ; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Asvold BO
    Int J Cancer; 2014 Dec; 135(11):2678-86. PubMed ID: 24752603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer. Dare to do less.
    Marshall E
    Science; 2014 Mar; 343(6178):1454-6. PubMed ID: 24675949
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of intra-operative margin management techniques in breast-conserving surgery: a standardised approach reduces the likelihood of residual disease without increasing operative time.
    Bolger JC; Solon JG; Khan SA; Hill AD; Power CP
    Breast Cancer; 2015 May; 22(3):262-8. PubMed ID: 23649303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer in West Virginia.
    Abraham J; Flanagan M; Hazard H; Jubelirer S; Tirona MT; Vona-Davis L
    W V Med J; 2009 Oct; 105 Spec No():54-9. PubMed ID: 19999267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case records of the Massachusetts General Hospital. Case 15-2010. An 85-year-old woman with mammographically detected early breast cancer.
    Muss HB; D'Alessandro HA; Brachtel EF
    N Engl J Med; 2010 May; 362(20):1921-8. PubMed ID: 20484399
    [No Abstract]   [Full Text] [Related]  

  • 19. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
    Glass AG; Lacey JV; Carreon JD; Hoover RN
    J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Extracapsular Invasion at Sentinel Lymph Nodes in Breast Cancer Patients with Sentinel Lymph Node Involvement.
    Shigematsu H; Taguchi K; Koui H; Ohno S
    Ann Surg Oncol; 2015 Jul; 22(7):2365-71. PubMed ID: 25476029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.